Who is sponsoring K19017-004?

K19017-004 is sponsored by Tongji Hospital.

What condition does K19017-004 study?

K19017-004 studies Ovarian Cancer.

What drugs are being tested in K19017-004?

Interventions: KM1, Chemotherapy.

What is the status of K19017-004?

K19017-004 is currently RECRUITING.

Last reviewed 2024-08-13 · How we verify

Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer (K19017-004)

NCT05684731 PHASE1 RECRUITING

The purpose of this study is to determine if KM1 is well tolerated with anti-tumor activity in patients diagnosed with recurrent or refractory ovarian cancer, and explore the Recommend Phase 2 Dose (RP2D) of KM1 in the treatment of patients with recurrent or refractory ovarian cancer.

Details

Lead sponsor	Tongji Hospital
Phase	PHASE1
Status	RECRUITING
Enrolment	30
Start date	Wed Feb 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Jun 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Ovarian Cancer

Interventions

KM1
Chemotherapy

Countries

China